Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Journal of Neuropathology and Experimental Neurology|May 3, 2018
Increased Oxidative Stress Exacerbates α-Synuclein Aggregation In VivoOwen Scudamore, Thomas CiossekPharmacotherapy|June 21, 2026
The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male VolunteersOwen Scudamore, Sven Wind, Rolf Grempler, et al.Analytical Biochemistry|September 18, 2007
A homogeneous cellular histone deacetylase assay suitable for compound profiling and robotic screeningThomas Ciossek, Heiko Julius, Heike Wieland, et al.Neurobiology of Aging|March 19, 2018
Age-related pathology after adenoviral overexpression of the leucine-rich repeat kinase 2 in the mouse striatumAstrid Kritzinger, Boris Ferger, Frank Gillardon, et al.Bioorganic & Medicinal Chemistry Letters|July 4, 2007
Trithiocarbonates: exploration of a new head group for HDAC inhibitorsFlorian Dehmel, Thomas Ciossek, Thomas Maier, et al.International Journal of Cancer|April 25, 2007
Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head groupThomas Beckers, Carmen Burkhardt, Heike Wieland, et al.Journal of Medicinal Chemistry|August 19, 2007
2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitorsSiavosh Mahboobi, Andreas Sellmer, Heymo Höcher, et al.Neuron|July 6, 2005
Opposing gradients of ephrin-As and EphA7 in the superior colliculus are essential for topographic mapping in the mammalian visual systemTahira Rashid, A Louise Upton, Aida Blentic, et al.Journal of Medicinal Chemistry|November 18, 2010
Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activitySiavosh Mahboobi, Andreas Sellmer, Matthias Winkler, et al.Journal of Medicinal Chemistry|March 24, 2009
Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylasesSiavosh Mahboobi, Stefan Dove, Andreas Sellmer, et al.Pageof 2